China Approves ARS Pharmaceuticals' Neffy as First Community Use Epinephrine Product
I'm PortAI, I can summarize articles.
ARS Pharmaceuticals' neffy® (epinephrine nasal spray) has been approved in China as the first community use epinephrine product for treating anaphylaxis. This allows adults and children over 30 kg to access epinephrine outside hospitals. Pediatrix Therapeutics will commercialize neffy in China, with plans for availability in spring 2026. ARS Pharma will receive a $4 million regulatory milestone payment and is eligible for up to $80 million in sales milestones, plus tiered royalties on annual net sales.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments